Chiesi USA

Chiesi USA is a commercial-stage, specialty pharmaceutical company and a key subsidiary of the Italy-based Chiesi Group. It operates with a dual therapeutic focus on Special Care (including neonatology and critical care) and Rare Diseases, leveraging its global parent's R&D capabilities. The company is actively advancing its pipeline, notably with a triple-combination inhaler for asthma under FDA review, while maintaining a strong commitment to environmental and social responsibility. As a private, family-owned entity, it combines long-term strategic vision with a dedicated commercial presence in the competitive U.S. market.

Focused expertise in formulation and delivery systems for respiratory, critical care, and rare disease therapies, leveraging global R&D from parent Chiesi Group.

In respiratory care, Chiesi competes with global pharmaceutical giants like GSK, AstraZeneca, and Boehringer Ingelheim. In neonatology and critical care, competition includes both large pharma and specialized hospital-focused companies. The rare disease space is fragmented, competing with both large biopharma rare disease units and smaller biotech firms.